Skip Navigation LinksHome > July 2008 - Volume 27 - Issue 7 > Double Boosted Protease Inhibitors, Saquinavir, and Lopinavi...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31816b4539
Original Studies

Double Boosted Protease Inhibitors, Saquinavir, and Lopinavir/Ritonavir, in Nucleoside Pretreated Children at 48 Weeks

Kosalaraksa, Pope MD*; Bunupuradah, Torsak MD†; Engchanil, Chulapan MD*; Boonrak, Pitch MSc†; Intasan, Jintana RN†; Lumbiganon, Pagakrong MD*; Burger, David MD‡; Ruxrungtham, Kiat MD†§; Schutz, Malte MD¶; Ananworanich, Jintanat MD†∥; the HIV-NAT 017 Study Team

Collapse Box


Objectives: To assess the 48-week efficacy, safety, pharmacokinetics, and resistance of double boosted protease inhibitors (PI), saquinavir (SQV), and lopinavir/ritonavir (LPV/r), in children who have failed nucleoside reverse transcription inhibitors /non-nucleoside reverse transcription inhibitors-based regimens.

Methods: Fifty children at 2 sites in Thailand were treated with standard dosing of SQV and LPV/r. CD4, HIV-RNA viral load (VL), plasma drug concentrations and safety laboratory evaluations were monitored. Virologic failure was defined as having 2 consecutive VL >400 copies/mL after week 12 of therapy. Intention to treat analysis was performed.

Results: Baseline data were a median age of 9.3 years (interquartile range [IQR]: 7.1–11.2), Center for Disease Control and Prevention (CDC) classification N:A:B:C 4%:14%:68%:14%, VL 4.8 log10 (IQR: 4.5–5.1), CD4 7% (IQR: 3–9.5). At 48 weeks, 3 had died of bacterial infection but no cases had progressed CDC classification. Median CD4% rise was 9 (IQR: 5–16) and median HIV RNA reduction was −2.8 log10 (IQR: −3.2 to −1.4), both P < 0.001. Thirty-nine (78%) and 32 (64%) children had VL <400 and <50 with significant differences between the 2 sites. Five children (10%) had VL failure as a result of poor adherence to the drug regimen but no one had major PI mutations. Median serum cholesterol and triglyceride increased significantly (+35 mg/dL, +37 mg/dL, respectively, both P < 0.001). Mean minimum plasma concentrations (Cmin) of LPV and SQV were 4.6 and 1.24 mg/L, respectively.

Conclusions: Double boosted SQV/LPV/r resulted in significant CD4 rise and VL decline at 48 weeks. Hyperlipidemia was common. Cmin of both PIs exceeded therapeutic concentrations. Poor adherence caused failure in 10%. No major PI mutations were found.

© 2008 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.